BioCardia (NASDAQ:BCDA) Stock Falls 5.5% – What’s Next?

BioCardia, Inc. (NASDAQ:BCDA) shares were down 5.5% during mid-day trading on Thursday. The stock traded as low as $0.92 and last traded at $0.9287. 50,039 shares changed hands during trading, a decline of 66% from the average daily volume of 146,650 shares. The stock had previously closed at $0.9824.

Wall Street Analyst Weigh In

BCDA has been the topic of several research reports. HC Wainwright restated a “buy” rating on shares of BioCardia in a research report on Monday, August 24th. Zacks Research raised shares of BioCardia from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 11th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioCardia in a report on Thursday, October 15th. Finally, Wall Street Zen upgraded BioCardia from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, BioCardia has an average rating of “Hold” and a consensus target price of $25.00.

BioCardia Stock Down 5.5%

The stock has a market capitalization of $14.06 million, a PE ratio of -1.45 and a beta of 0.62. The stock has a fifty day moving average of $1.06 and a 200-day moving average of $1.02.

BioCardia (NASDAQ:BCDA) last issued its earnings results on Wednesday, August 12th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.05. Equities research analysts expect that BioCardia, Inc. will post -0.71 EPS for the current year.

About BioCardia

BioCardia, Inc is a biotechnology company focused on developing regenerative cell therapies and related delivery systems for cardiovascular diseases. The company’s programs are designed to repair or improve heart tissue and function in patients with conditions such as chronic heart failure and refractory angina caused by coronary artery disease.

BioCardia’s lead programs include CardiAMP Cell Therapy, an investigational autologous treatment that uses a patient’s own bone marrow-derived cells, and CardiALLO, an investigational allogeneic cell therapy based on donor-derived cells.